MEDCL Share Price Performance
€28.22
11.92 (73.13%)
19.6% undervalued intrinsic discount
€35.10
Fair Value
Price €28.22
AnalystConsensusTarget €35.10
AnalystHighTarget €48.54
AnalystLowTarget €27.00
Fair Value€35.10
Share Pricen/a
MedinCell S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
MEDCL Community Narratives
AN
Fair Value €35.1 19.6% undervalued intrinsic discount
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
2users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value €48.54 41.9% undervalued intrinsic discount
Long Acting Injectables Will Drive Major Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value €27 4.5% overvalued intrinsic discount
Long Acting Injectables Will Face Setbacks Before Delivering The Upside I Expect
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.Read more
216
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
€35.1
19.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
61.84% p.a.
Profit Margin
53.16%
Future PE
18.97x
Price in 2029
€41.78
Long Acting Injectables Will Face Setbacks Before Delivering The Upside I Expect
Catalysts About MedinCell MedinCell develops long acting injectable therapies based on its formulation technology, working with partners to bring these products to market. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€27
4.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
43.69% p.a.
Profit Margin
38.04%
Future PE
29.3x
Price in 2029
€32.32
Long Acting Injectables Will Drive Major Long Term Upside Potential
Catalysts About MedinCell MedinCell develops long acting injectable therapies using its proprietary technology to improve treatment adherence and patient outcomes across multiple disease areas. What are the underlying business or industry changes driving this perspective?Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€48.54
41.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
61.45% p.a.
Profit Margin
94.51%
Future PE
14.43x
Price in 2028
€58.11
Trending Discussion
Recently Updated Narratives
AN
MEDCL: Index Inclusion Will Support Future Upside Potential
Fair Value: €35.1 19.6% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Acting Injectables Will Face Setbacks Before Delivering The Upside I Expect
Fair Value: €27 4.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Acting Injectables Will Drive Major Long Term Upside Potential
Fair Value: €48.54 41.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MedinCell S.A. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Jun 16, 2026
- -0.60
- 100.00%
- -61.49%
- -232.2%
About MEDCL
- Founded
- 2003
- Employees
- 145
- CEO
- WebsiteView website
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
